Wall Street brokerages expect Inspire Medical Systems (NASDAQ:INSP) to report earnings per share of ($0.32) for the current quarter, Zacks reports. Three analysts have provided estimates for Inspire Medical Systems’ earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.29). The firm is expected to issue its next quarterly earnings report on Tuesday, February 5th.

According to Zacks, analysts expect that Inspire Medical Systems will report full-year earnings of ($6.01) per share for the current fiscal year, with EPS estimates ranging from ($6.01) to ($6.00). For the next year, analysts forecast that the business will post earnings of ($1.36) per share, with EPS estimates ranging from ($1.44) to ($1.28). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Inspire Medical Systems.

Inspire Medical Systems (NASDAQ:INSP) last posted its earnings results on Tuesday, November 6th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.13. The business had revenue of $13.10 million during the quarter, compared to analysts’ expectations of $12.86 million. During the same quarter in the previous year, the business earned ($3.42) EPS. Inspire Medical Systems’s revenue for the quarter was up 79.9% on a year-over-year basis.

A number of equities analysts have recently commented on the stock. Berenberg Bank assumed coverage on shares of Inspire Medical Systems in a research report on Wednesday, November 28th. They issued a “sell” rating and a $31.00 price objective for the company. Zacks Investment Research lowered shares of Inspire Medical Systems from a “hold” rating to a “sell” rating in a research report on Wednesday, November 21st. Finally, Leerink Swann assumed coverage on shares of Inspire Medical Systems in a research report on Monday, October 29th. They issued an “outperform” rating and a $57.00 price objective for the company. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $39.63.

In other news, VP Randy Ban sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $40.37, for a total value of $403,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Timothy P. Herbert sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 18th. The shares were sold at an average price of $42.88, for a total transaction of $643,200.00. The disclosure for this sale can be found here. Insiders sold 51,300 shares of company stock valued at $2,180,030 over the last 90 days.

A number of institutional investors have recently made changes to their positions in the business. Rhumbline Advisers purchased a new position in shares of Inspire Medical Systems in the second quarter worth $243,000. Bank of New York Mellon Corp purchased a new position in shares of Inspire Medical Systems in the second quarter worth $1,902,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Inspire Medical Systems in the second quarter worth $1,451,000. BlackRock Inc. purchased a new position in shares of Inspire Medical Systems in the second quarter worth $19,624,000. Finally, FMR LLC purchased a new position in shares of Inspire Medical Systems in the second quarter worth $11,340,000.

Shares of INSP stock traded up $1.55 during trading hours on Wednesday, reaching $50.90. The stock had a trading volume of 384,600 shares, compared to its average volume of 379,609. Inspire Medical Systems has a 12 month low of $22.50 and a 12 month high of $57.87.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Featured Article: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Inspire Medical Systems (INSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.